To reflect its integrated drug discovery service offering
Sygnature Chemical Services, a UK provider of drug discovery services to the pharmaceutical industry, has changed its name to Sygnature Discovery to reflect the range of integrated drug discovery services that it offers.
The firm currently employs more than 50 laboratory based medicinal chemists and in vitro biologists in its purpose-built facility in BioCity Nottingham.
Simon Hirst, Sygnature’s ceo, said: ‘When I founded Sygnature Chemical Services in 2004 with 5½ staff and myself working in the laboratory, my ambition was to create an organisation which offered integrated drug discovery services to the global pharmaceutical industry. Seven years later, that objective has been achieved.’
Over the past two years, Sygnature has doubled in size and has recruited 10 medicinal chemists and biologists from AstraZeneca r&d Charnwood, which increases its drug discovery experience in inflammatory respiratory diseases, CNS and CV diseases.
The firm has also started construction of a third laboratory, which from November will house 25 more scientists, and has filed 20 patent applications with clients.